Sarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Stock investors acquired 6,583 put options on the stock. This represents an increase of approximately 246% compared to the average volume of 1,901 put options.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on SRPT. Royal Bank of Canada cut Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and lowered their price objective for the company from $161.00 to $87.00 in a research report on Monday, March 31st. HC Wainwright raised shares of Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 price target on the stock in a report on Wednesday, April 2nd. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research note on Wednesday, March 19th. Cantor Fitzgerald restated an "overweight" rating and set a $163.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Finally, Needham & Company LLC dropped their target price on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a report on Thursday, April 3rd. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $163.18.

Remove Ads

Sarepta Therapeutics Trading Down 2.1 %

Shares of NASDAQ SRPT traded down $1.09 during midday trading on Tuesday, hitting $51.32. The company's stock had a trading volume of 1,440,378 shares, compared to its average volume of 1,336,678. Sarepta Therapeutics has a 12-month low of $50.61 and a 12-month high of $173.25. The firm has a market cap of $4.98 billion, a P/E ratio of 40.87 and a beta of 0.93. The business's 50 day moving average is $95.66 and its two-hundred day moving average is $113.09. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.70% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SRPT. Quantbot Technologies LP purchased a new position in shares of Sarepta Therapeutics during the third quarter worth approximately $237,000. Captrust Financial Advisors grew its stake in Sarepta Therapeutics by 15.2% in the third quarter. Captrust Financial Advisors now owns 3,871 shares of the biotechnology company's stock worth $483,000 after purchasing an additional 511 shares in the last quarter. Stifel Financial Corp increased its holdings in Sarepta Therapeutics by 99.3% during the 3rd quarter. Stifel Financial Corp now owns 37,207 shares of the biotechnology company's stock worth $4,647,000 after purchasing an additional 18,537 shares during the period. Soros Fund Management LLC bought a new stake in Sarepta Therapeutics during the 3rd quarter valued at $25,800,000. Finally, Wellington Management Group LLP lifted its holdings in shares of Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after buying an additional 665,087 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.